Anti-allergic non-woven fabric and preparation method thereof

Abstract

The invention discloses an anti-allergic non-woven fabric and a preparation method thereof, and belongs to the technical field of preparation of novel fibers and composite materials, and the non-woven fabric is structurally characterized in that a functional coating comprising a base layer and a slow-release layer is fixed on a non-woven fabric base material through a cross-linking agent. The core of the preparation method is that the non-woven fabric base material is firstly subjected to plasma activation, then the non-woven fabric base material is soaked in a micromolecular anti-allergic agent solution and an anti-allergic microcapsule dispersion liquid in two steps, and finally the functional coating is firmly fixed through baking crosslinking. Through the synergistic effect of a physical structure and chemical slow release, the long-term effect and safety of the anti-allergic function are achieved, and the defects that in the prior art, functional components are prone to falling off, and the period of validity is short are effectively overcome.

Description

Technical Field

[0001] This invention relates to the technical field of novel fiber and composite material preparation, and in particular to an anti-allergy nonwoven fabric and its preparation method. Background Technology

[0002] Nonwoven fabrics have been widely used in medical, hygiene, filtration, and home furnishing fields due to their diverse manufacturing processes, low cost, and adjustable properties. Especially in the medical field, such as dressings, surgical gowns, and masks, higher requirements are placed on the functionality of nonwoven fabrics, with anti-allergy and antibacterial properties being key indicators.

[0003] Currently, methods for imparting functionality to nonwoven fabrics mainly fall into two categories: one is modifying fibers to form the fabric, and the other is finishing the already formed nonwoven fabric. Finishing methods are more widely used due to their simplicity and lower cost. In existing technologies, common anti-allergy / antibacterial finishing methods are mostly simple impregnation or spraying processes, which involve immersing the nonwoven fabric substrate in a solution containing functional agents, followed by drying to fix it.

[0004] For example, Chinese patent document CN218966321U discloses a medical nonwoven fabric with anti-allergy and antibacterial properties. It mainly achieves its functionality and ease of use through a multi-layer structure design, such as setting antibacterial pads, soft layers, and reinforcing pads, as well as a physical tear-resistant structure. Its core function depends on the material itself, such as the inherent properties of the antibacterial pads.

[0005] However, this type of existing technology has the following obvious drawbacks: 1. Single and passive function: As shown in the prior art, its anti-allergy ability may mainly rely on the physical barrier (soft bristles) and the inherent characteristics of the selected antibacterial pad material, lacking the ability to actively and continuously release anti-allergy agents; its function is static, and once the surface is contaminated or covered, the effect is greatly reduced.

[0006] 2. Insufficient functional durability: If the traditional impregnation method is used to load the medication, the adhesion between the medication and the fiber is mostly physical adsorption, resulting in weak bonding. When in contact with liquids, such as wound exudate, sweat, or when subjected to friction, the medication is easily detached and lost quickly, leading to a short functional lifespan and failing to meet the needs of long-term care.

[0007] 3. Potential safety risks: In order to achieve results in a short period of time, traditional processes may increase the initial concentration of the drug, which may lead to excessively high local concentrations, causing irritation to sensitive skin and defeating the original purpose of anti-allergy.

[0008] 4. Neglecting synergistic effects: Existing technologies mostly focus on single functions, such as antibacterial or anti-allergic, or simple physical structure superposition, failing to design a functional system at the molecular level that can work synergistically and respond intelligently, such as simultaneously achieving multiple effects such as allergen isolation, long-lasting anti-allergy, and gentle care.

[0009] Therefore, there is an urgent need in this field for a technical solution that can fundamentally solve the problems of drug loading stability, long-term release and safety of use, and provide a new type of nonwoven fabric and its production process that not only has anti-allergy ability, but also can actively, controllably and persistently exert its efficacy, and has good compatibility with the human body and the environment. Summary of the Invention

[0010] Therefore, it is necessary to address the shortcomings of existing anti-allergy nonwoven fabrics, such as poor functional durability, risk of irritation, and passive functional modes, by providing a nonwoven fabric that can actively, long-lastingly, and controllably release anti-allergy components.

[0011] Another object of the present invention is to provide a method for preparing the above-mentioned nonwoven fabric, which achieves high loading, uniform distribution and firm bonding of functional components on the fibers through an innovative step-by-step impregnation and fixation method.

[0012] A method for preparing an anti-allergic nonwoven fabric, comprising the following steps: S1. Substrate pretreatment: The nonwoven fabric substrate is subjected to low-temperature plasma treatment to activate the fiber surface; S2. Primary impregnation: The pretreated nonwoven fabric is impregnated in the primary impregnation solution and rolled to control the liquid retention rate; S3. Pre-drying: Pre-drying the nonwoven fabric that has been initially impregnated; S4. Secondary impregnation: The pre-dried nonwoven fabric is impregnated in the secondary impregnation solution and rolled to control the liquid carry-over rate. S5. Baking and fixing: The nonwoven fabric that has been secondary impregnated is baked to allow the crosslinking agent to react and form a stable functional coating on the fiber. S6. Finishing: The baked nonwoven fabric is washed, softened and dried to obtain the finished product; The primary impregnation solution contains a small molecule anti-allergy agent and a first cross-linking agent; The secondary impregnation solution contains anti-allergy microcapsules and a second cross-linking agent.

[0013] Specifically, the crosslinking agent in the primary impregnation solution and the secondary impregnation solution is independently selected from at least one of citric acid, butanetetracarboxylic acid, and polycarboxylic acid.

[0014] Specifically, the small molecule anti-allergy agent is selected from at least one of oat alkaloids, dipotassium glycyrrhizate, baicalin, and ketotifen.

[0015] Specifically, the core component of the anti-allergy microcapsule is selected from at least one of quercetin, andrographolide, zinc oxide / spironolactone complex, and glycyrrhetinic acid; the wall material of the anti-allergy microcapsule is at least one of chitosan, gelatin, sodium alginate, and poloxamer.

[0016] Specifically, the primary impregnation solution contains at least one functional adjuvant selected from ceramides, epidermal growth factor, ε-polylysine, and rosin quaternary ammonium salt derivatives.

[0017] Specifically, the liquid carryover rate in step S2 is controlled at 70%-80%, and the liquid carryover rate in step S4 is controlled at 60%-70%.

[0018] Specifically, the pre-drying temperature in step S3 is 90-110℃ and the time is 1-3 minutes; the baking temperature in step S5 is 120-150℃ and the time is 2-5 minutes.

[0019] Furthermore, a nonwoven fabric prepared based on the above-described method for preparing anti-allergy nonwoven fabric comprises: a nonwoven fabric substrate and a functional coating fixed thereon by a crosslinking agent; the functional coating comprises: The base layer is formed by small molecule anti-allergy agents bonded to the fiber surface and internal pores by cross-linking agents; The sustained-release layer consists of anti-allergy microcapsules interlaced and fixed onto the base layer and between the nonwoven fibers by a cross-linking agent.

[0020] That is, the nonwoven fabric includes a nonwoven substrate and a functional coating fixed thereon by a crosslinking agent; the functional coating includes a base layer and a slow-release layer.

[0021] Specifically, the nonwoven fabric substrate is activated carbon fiber nonwoven fabric or calcium alginate fiber nonwoven fabric.

[0022] Specifically, the nonwoven fabric conforms to the ISO 4333-2022 standard, and after five standard washes, its histamine inhibition rate remains above 80%.

[0023] Compared with the prior art, the present invention has the following technical effects: Long-lasting and controlled release: Microencapsulation technology enables the slow and controlled release of anti-allergy ingredients, ensuring that the product maintains its effective activity even after long-term use or repeated light wiping. Simulated testing showed that after five washes according to ISO4333-2022 standards, the anti-allergy inhibition rate remained above 80%.

[0024] High load capacity and high strength: The step-by-step impregnation process combined with cross-linking technology allows functional components to not only adhere to the fiber surface but also penetrate into the internal pores, forming a stable structure through chemical bonding, which greatly reduces the loss rate of components.

[0025] Safe and gentle: The sustained-release properties of microcapsules avoid direct contact with high-concentration medications, maintaining a stable low effective concentration and significantly reducing the risk of skin allergies and irritation. The use of natural anti-allergy ingredients further enhances biocompatibility.

[0026] Synergistic effect: The activated carbon fiber / calcium alginate substrate provides the "first line of defense" for physical adsorption / isolation of allergens, which works synergistically with the "second line of defense" of chemical anti-allergy agents to achieve a dual anti-allergy mechanism of "physical + chemical", which is more effective than a single mode.

[0027] The process is highly adaptable: it does not require special or expensive equipment and can be implemented by modifying existing textile dyeing and finishing production lines, making it easy to promote industrialization. Attached Figure Description

[0028] Figure 1 This is a process flow diagram of the preparation method of an anti-allergy nonwoven fabric according to the present invention. Detailed Implementation

[0029] To make the above-mentioned objects, features, and advantages of the present invention more apparent and understandable, specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings. Many specific details are set forth in the following description to provide a thorough understanding of the present invention. However, the present invention can be practiced in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0030] In the description of this invention, it should be understood that the terms "center," "longitudinal," "lateral," "length," "width," "thickness," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," "clockwise," "counterclockwise," "axial," "radial," and "circumferential" indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings. They are used only for the convenience of describing this invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limitations on this invention.

[0031] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of that feature. In the description of this invention, "a plurality of" means at least two, such as two, three, etc., unless otherwise explicitly specified.

[0032] In this invention, unless otherwise explicitly specified and limited, the terms "installation," "connection," "linking," and "fixing," etc., should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral part; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication of two components or the interaction between two components, unless otherwise explicitly limited. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances.

[0033] In this invention, unless otherwise explicitly specified and limited, "above" or "below" the second feature can mean that the first feature is in direct contact with the second feature, or that the first feature is in indirect contact with the second feature through an intermediate medium. Furthermore, "above," "over," and "on top" of the second feature can mean that the first feature is directly above or diagonally above the second feature, or simply that the first feature is at a higher horizontal level than the second feature. "Below," "below," and "under" the second feature can mean that the first feature is directly below or diagonally below the second feature, or simply that the first feature is at a lower horizontal level than the second feature.

[0034] It should be noted that when an element is referred to as being "fixed to" or "set on" another element, it can be directly on the other element or there may be an intervening element. When an element is considered to be "connected to" another element, it can be directly connected to the other element or there may be an intervening element. The terms "vertical," "horizontal," "upper," "lower," "left," "right," and similar expressions used herein are for illustrative purposes only and do not represent the only possible implementation.

[0035] Specifically, the present invention provides an anti-allergy nonwoven fabric, which includes the following technical solutions: Option 1: A long-lasting anti-allergy nonwoven fabric, wherein the nonwoven fabric comprises a nonwoven substrate and a functional coating fixed thereon by a crosslinking agent; the functional coating includes: Base layer: formed by small molecule anti-allergy agents bonded to the fiber surface and internal pores by cross-linking agents; Sustained-release layer: composed of microcapsules coated with anti-allergy ingredients, which are interlaced and fixed between the base layer and non-woven fibers by a cross-linking agent; The nonwoven fabric substrate is preferably activated carbon fiber nonwoven fabric or calcium alginate fiber nonwoven fabric.

[0036] The anti-allergy ingredient is selected from at least one of glycyrrhetinic acid, baicalin, quercetin, olamin and their derivatives.

[0037] The wall material of the microcapsules is a biocompatible polymer, such as chitosan, gelatin, or sodium alginate.

[0038] The crosslinking agent is an environmentally friendly crosslinking agent, such as citric acid or butanetetracarboxylic acid.

[0039] Option 2: Figure 1 As shown, a method for preparing the above-mentioned anti-allergy nonwoven fabric includes the following steps: S1. Substrate pretreatment: The nonwoven fabric substrate is subjected to low-temperature plasma treatment to activate the fiber surface.

[0040] S2. Primary impregnation: The pretreated nonwoven fabric is impregnated in a solution containing a small molecule anti-allergy agent and a first crosslinking agent, and the liquid carry-over rate is controlled.

[0041] S3. Pre-drying: Pre-dry the nonwoven fabric after primary impregnation at 90-110℃.

[0042] S4. Secondary impregnation: The pre-dried nonwoven fabric is impregnated in a dispersion containing anti-allergy microcapsules and a second crosslinking agent, and the impregnation is carried out while controlling the liquid carry-over rate.

[0043] S5. Baking and Fixation: Baking at 120-150℃ for 2-5 minutes allows the crosslinking agent to react fully, forming a stable three-dimensional network structure that firmly fixes the base layer and the slow-release layer onto the fiber.

[0044] S6. Finishing: Washing, softening, and drying processes are carried out to obtain the finished product.

[0045] The present invention will be further described in detail below with reference to specific embodiments: Example 1

[0046] Substrate: 50g / m² calcium alginate spunlace nonwoven fabric.

[0047] Primary impregnation solution: an aqueous solution of 2% carboxymethyl chitosan (small molecule anti-allergy agent) and 1.5% citric acid (crosslinking agent).

[0048] Secondary impregnation solution: an aqueous dispersion containing 6% glycyrrhetinic acid-chitosan microcapsules (particle size 5-20μm) and 2.5% citric acid.

[0049] Preparation method of Example 1: 1. Plasma treatment, set power to 2kW and speed to 15m / min; 2. One dip and one roll, primary impregnation solution, liquid retention rate 75%; 3. Pre-dry at 105℃ for 2 minutes; 4. One dip and one roll, secondary impregnation solution, liquid carryover rate 65%; 5. Bake at 135℃ for 4 minutes; 6. Wash with warm water, then set and dry at 130℃.

[0050] Comparative example: The traditional one-step impregnation method is adopted, which involves mixing the primary and secondary impregnation solutions and then impregnating them in one go, with the remaining conditions the same as in Example 1.

[0051] Test Results: The anti-allergy performance of Example 1 and the comparative product was tested according to ISO 4333-2022, including the inhibition rate of histamine. The results showed that initially, both exhibited histamine inhibition rates above 95%, indicating comparable performance. However, after three standard washes, the inhibition rate of the comparative product decreased to below 50%, while the inhibition rate of Example 1 remained above 85%. This demonstrates the significant advantage of the anti-allergy nonwoven fabric of this invention in terms of functional durability.

[0052] Furthermore, several formulation examples are presented below. These formulation examples can be combined with the aforementioned stepwise impregnation process, or they can be adjusted according to actual production conditions, as detailed below: Example 1 of the synergistic soothing formula focuses on rapid response and long-lasting soothing. This formula aims to achieve both immediate soothing and long-term anti-allergy effects, and is suitable for skin-friendly products such as face masks and wipes. It can combine the rapid action of small molecules with the long-lasting release of microcapsules, and add soothing ingredients to enhance the user experience. Therefore, it can be applied to high-end personal hygiene products, sensitive skin care products, etc.

[0053] The specific formulation of the synergistic soothing formula in Example 1 is as follows, by weight percentage: Primary impregnation solution: Main anti-allergy agent: Oat alkaloids 1.5% (w / w) - naturally sourced, with excellent antihistamine and antipruritic effects, small molecular weight, and easy and rapid penetration; Synergistic soothing agent: Dipotassium glycyrrhizate 0.5% (w / w) - a classic anti-inflammatory and soothing ingredient that works synergistically with oat alkaloids; Crosslinking agent: Citric acid 2.0% (w / w); Solvent: Deionized water, balance; Secondary impregnation solution: Sustained-release microcapsules: Quercetin-chitosan microcapsules 4.0% (w / w) - Quercetin is a powerful natural anti-allergy agent that can stabilize mast cells, but its bioavailability is low when used directly. Microencapsulation enables long-lasting release. Skin barrier repair agent: Ceramide NP 0.3% (w / w) - helps repair damaged skin barrier and reduces the risk of allergies from the root; Crosslinking agent: 1.5% citric acid (w / w); Dispersion medium: Deionized water (balance).

[0054] The expected effects of the synergistic soothing formulation in Example 1 are as follows: upon contact with the skin, oat alkaloids and dipotassium glycyrrhizate are rapidly released, relieving itching and redness within minutes. Meanwhile, the quercetin microcapsules slowly rupture under friction and sweat, providing sustained anti-allergic protection for several hours. Furthermore, ceramides help repair the skin, and long-term use can improve skin tolerance.

[0055] Example 2 of the defensive and repair-type formula focuses on isolating allergens and actively repairing. This formula can provide physical and chemical dual protection for wounded or extremely sensitive skin and promote repair. It can use the film-forming properties of polymers to isolate external stimuli while loading anti-allergy and repairing ingredients. Therefore, it can be applied to medical dressings, wound contact layers, etc.

[0056] The specific formulation of the second example of the defensive and repairing formula is as follows, by weight percentage: Primary impregnation solution: Main anti-allergy agent: Baicalin 2.0% (w / w) - has broad-spectrum anti-inflammatory and anti-allergic activities and is stable; Film-forming agent: Carboxymethyl chitosan 1.0% (w / w) - can form a hydrophilic gel film on the fiber surface, which not only isolates allergens but also provides a matrix for drug release; Crosslinking agent: Butanetetracarboxylic acid 1.5% (w / w); Solvent: Deionized water, balance; Secondary impregnation solution: Sustained-release microcapsules: Zinc oxide / spironolactone composite microcapsules 5.0% (w / w) - Zinc oxide has astringent, antibacterial and physical barrier effects; spironolactone is a novel anti-inflammatory agent, and the two are combined to achieve synergistic effects; Active repair factor: Epidermal growth factor at 100ppm - even a very low concentration can effectively promote epithelial cell growth and accelerate wound healing; Crosslinking agent: Butanetetracarboxylic acid 1.0% (w / w); Dispersion medium: Deionized water (balance).

[0057] The expected effect of the second example of the defensive and repairing formulation is as follows: Carboxymethyl chitosan forms a moist gel environment under the action of wound exudate, which can block external allergens and bacteria without adhering to the wound surface. Then, in the wound microenvironment, i.e., under specific pH or enzyme conditions, the microcapsules can more easily release their contents, achieving intelligent drug delivery. Finally, epidermal growth factor acts directly on the wound surface, accelerating the healing process, and is particularly suitable for skin damage caused by allergic dermatitis.

[0058] Example 3 of the potent antiviral and anti-allergy composite formulation emphasizes multifunctionality. This formulation aims to expand the functionality of nonwoven fabrics, enabling them to possess antiviral and antibacterial capabilities in addition to their anti-allergy properties, making them suitable for scenarios with high protection requirements. Specifically, Example 3 of the formulation combines anti-allergy ingredients with naturally derived broad-spectrum antiviral agents to achieve dual protection against allergies and viruses. Therefore, it can be applied to air filtration materials, the core layer of protective masks, and wiping cloths for public environments.

[0059] Specifically, the specific formula of the potent antiviral and anti-allergy compound formula in Example 3 is as follows, by weight percentage: Primary impregnation solution: Main anti-allergy agent: Ketotifen 0.05% (w / w) - a potent mast cell stabilizer, requiring only a small dosage and achieving high efficacy; Natural antiviral agent: Rosin quaternary ammonium salt derivative 1.0% (w / w) - a modified natural rosin product, which has a good inactivation effect on enveloped viruses (such as influenza virus and coronavirus) and can adsorb negatively charged allergens (such as pollen protein) through its cationic properties. Crosslinking agent: Citric acid 2.0% (w / w); Solvent: A mixture of deionized water and a small amount of ethanol to dissolve ketotifen; Secondary impregnation solution: Sustained-release microcapsules: Andrographolide-Poloxamer microcapsules 3.5% (w / w) - Andrographolide has multiple effects such as anti-inflammatory, antiviral, and immunomodulatory effects; Synergistic antimicrobial agent: ε-polylysine 0.8% (w / w) - a natural food-grade antimicrobial agent that prevents microbial growth; Crosslinking agent: 1.5% citric acid (w / w); Dispersion medium: Deionized water (balance).

[0060] The expected effects of the potent antiviral and anti-allergic compound formulation in Example 3 are as follows: First, it can inhibit allergic reactions through ketotifen and andrographolide, and inactivate viruses through rosin quaternary ammonium salt and andrographolide, greatly expanding the product's application range. Moreover, microencapsulation technology ensures sustained release of andrographolide, extending the protective time. Furthermore, the introduction of ε-polylysine makes the nonwoven fabric less prone to mold and bacterial growth in humid environments, improving the product's durability and safety.

[0061] In summary, the present invention provides an anti-allergy nonwoven fabric and its preparation method, which effectively solves the technical problems of poor functional durability and easy irritation of existing anti-allergy nonwoven fabrics through stepwise impregnation and microencapsulation technology, and achieves long-lasting, safe and controllable release of anti-allergy components.

[0062] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0063] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. A method for preparing an anti-allergic nonwoven fabric, characterized in that, It includes the following steps: S1. Substrate pretreatment: The nonwoven fabric substrate is subjected to low-temperature plasma treatment to activate the fiber surface; S2. Primary impregnation: The pretreated nonwoven fabric is impregnated in the primary impregnation solution and rolled to control the liquid retention rate; S3. Pre-drying: Pre-drying the nonwoven fabric that has been initially impregnated; S4. Secondary impregnation: The pre-dried nonwoven fabric is impregnated in the secondary impregnation solution and rolled to control the liquid carry-over rate. S5. Baking and fixing: The nonwoven fabric that has been secondary impregnated is baked to allow the crosslinking agent to react and form a stable functional coating on the fiber. S6. Finishing: The baked nonwoven fabric is washed, softened and dried to obtain the finished product; The primary impregnation solution contains a small molecule anti-allergy agent and a first cross-linking agent; The secondary impregnation solution contains anti-allergy microcapsules and a second cross-linking agent.

2. The method for preparing an anti-allergic nonwoven fabric according to claim 1, characterized in that: The crosslinking agent in the primary impregnation solution and the secondary impregnation solution is independently selected from at least one of citric acid, butanetetracarboxylic acid, and polycarboxylic acid.

3. The method for preparing an anti-allergic nonwoven fabric according to claim 1, characterized in that: The small molecule anti-allergy agent is selected from at least one of oat alkaloids, dipotassium glycyrrhizate, baicalin, and ketotifen.

4. The method for preparing an anti-allergic nonwoven fabric according to claim 1, characterized in that: The core component of the anti-allergy microcapsule is selected from at least one of quercetin, andrographolide, zinc oxide / spironolactone complex, and glycyrrhetinic acid; the wall material of the anti-allergy microcapsule is at least one of chitosan, gelatin, sodium alginate, and poloxamer.

5. The method for preparing an anti-allergic nonwoven fabric according to claim 1, characterized in that: The primary impregnation solution contains at least one functional adjuvant selected from ceramides, epidermal growth factor, ε-polylysine, and rosin quaternary ammonium salt derivatives.

6. The method for preparing an anti-allergic nonwoven fabric according to claim 1, characterized in that: The liquid carryover rate in step S2 is controlled at 70%-80%, and the liquid carryover rate in step S4 is controlled at 60%-70%.

7. The method for preparing an anti-allergic nonwoven fabric according to claim 1, characterized in that: The pre-drying temperature in step S3 is 90-110℃, and the time is 1-3 minutes; the baking temperature in step S5 is 120-150℃, and the time is 2-5 minutes.

8. A nonwoven fabric prepared by the method for preparing anti-allergic nonwoven fabric according to any one of claims 1-7, characterized in that: The nonwoven fabric includes a nonwoven fabric substrate and a functional coating fixed thereon by a crosslinking agent; the functional coating includes: The base layer is formed by small molecule anti-allergy agents bonded to the fiber surface and internal pores by cross-linking agents; The sustained-release layer consists of anti-allergy microcapsules interlaced and fixed onto the base layer and between the nonwoven fibers by a cross-linking agent.

9. The nonwoven fabric according to claim 8, characterized in that: The nonwoven fabric substrate is activated carbon fiber nonwoven fabric or calcium alginate fiber nonwoven fabric.

10. The nonwoven fabric according to claim 8, characterized in that: The nonwoven fabric conforms to the ISO 4333-2022 standard, and after five standard cleanings, its histamine inhibition rate remains above 80%.

Images